VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 468 filers reported holding VALEANT PHARMACEUTICALS INTL in Q4 2015. The put-call ratio across all filers is 0.90 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $2,000 | +100.0% | 70 | 0.0% | 0.00% | – |
| Q1 2018 | $1,000 | 0.0% | 70 | 0.0% | 0.00% | – |
| Q4 2017 | $1,000 | -75.0% | 70 | -74.1% | 0.00% | -100.0% |
| Q3 2017 | $4,000 | -20.0% | 270 | 0.0% | 0.00% | -50.0% |
| Q2 2017 | $5,000 | -37.5% | 270 | -62.8% | 0.00% | -33.3% |
| Q1 2017 | $8,000 | -27.3% | 725 | 0.0% | 0.00% | -25.0% |
| Q4 2016 | $11,000 | -15.4% | 725 | +38.1% | 0.00% | -33.3% |
| Q3 2016 | $13,000 | +18.2% | 525 | 0.0% | 0.01% | +20.0% |
| Q2 2016 | $11,000 | -21.4% | 525 | 0.0% | 0.01% | -28.6% |
| Q1 2016 | $14,000 | -73.6% | 525 | 0.0% | 0.01% | -74.1% |
| Q4 2015 | $53,000 | -43.6% | 525 | 0.0% | 0.03% | -47.1% |
| Q3 2015 | $94,000 | -19.7% | 525 | 0.0% | 0.05% | -15.0% |
| Q2 2015 | $117,000 | +12.5% | 525 | 0.0% | 0.06% | +13.2% |
| Q1 2015 | $104,000 | +38.7% | 525 | 0.0% | 0.05% | +35.9% |
| Q4 2014 | $75,000 | – | 525 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 6,050,442 | $763,082,000 | 30.78% |
| LeVasseur Capital Partners LLC | 190,404 | $24,014,000 | 29.50% |
| FARLEY CAPITAL L.P. | 333,081 | $42,008,000 | 27.09% |
| Ruane, Cunniff & Goldfarb | 34,298,384 | $4,325,712,000 | 23.07% |
| ValueAct Holdings | 18,923,877 | $2,386,679,000 | 17.64% |
| Tesuji Partners | 1,368,040 | $172,537,000 | 17.22% |
| Brahman Capital Corp. | 3,902,877 | $492,231,000 | 13.63% |
| Arrow Capital Management, LLC | 197,500 | $24,909,000 | 13.60% |
| Hound Partners | 2,851,175 | $359,590,000 | 13.45% |
| Ratan Capital Management LP | 731,960 | $92,315,000 | 13.09% |